ClinicalTrials.gg
RecruitingNCT07640893Updated Jun 11, 2026

A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease

A Phase 2 interventional study of SR604 in Von Willebrand Disease (VWD), sponsored by Shanghai RAAS Blood Products Co., Ltd.. Recruiting at 9 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Shanghai RAAS Blood Products Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2025, registered Jun 2026).
  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in patients with von Willebrand disease.

02

Conditions studied

  • Von Willebrand Disease (VWD)
03

In context

von Willebrand Diseases

96 studies on the registry are indexed under von Willebrand Diseases; 25 are open to participants now.

This study's planned enrollment of 24 is close to the median of 25 across 41 interventional studies indexed under von Willebrand Diseases.

Browse von Willebrand Diseases studies →

Lead sponsor

Shanghai RAAS Blood Products Co., Ltd. is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must meet ALL of the following inclusion criteria to be enrolled:

    1. Age >= 18 years and \<= 65 years at the time of signing , regardless of sex;
    2. At screening, patients with a confirmed diagnosis of von Willebrand disease (VWD) with documented evidence and a defined VWD subtype;
    3. At least 4 new bleeding episodes within 6 months prior to screening;
    4. No active bleeding symptoms prior to the first dose;
    5. The subject or impartial witness fully understands and is able to comply with the protocol requirements, is willing to complete the study as planned, and voluntarily agrees to provide biological samples for testing as required by the protocol; is able to understand the procedures and methods of this clinical trial, provides voluntary participation after full informed consent, and personally signs the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Patients meeting ANY of the following exclusion criteria will not be enrolled:

    1. Known history of to the drug formulation or any of its components;
    2. Intolerance to subcutaneous injection or presence of other local skin abnormalities or dermatological conditions that may affect drug administration and safety assessment;
    3. Meeting any of the following criteria at screening:

      1. \< 60 g/L;
      2. count \< 80 x 10\^9/L;
      3. Hepatic or renal dysfunction: (ALT) or aspartate aminotransferase (AST) >= 2.5 x (ULN), or total >= 1.5 x ULN; or serum creatinine (Cr) >= 1.5 x ULN;
    4. Positive for anti- (HIV) antibody;
    5. Presence of any bleeding disorder other than von Willebrand disease [hemophilia A or B, congenital coagulation factor VII deficiency, acquired von Willebrand disease (AVWS), platelet-type VWD, inherited platelet disorders, etc.]; or significantly abnormal coagulation parameters due to diseases other than von Willebrand disease (e.g., platelet disorders, vitamin K deficiency, etc.);
    6. Presence of protein C deficiency or protein S deficiency;
    7. History of thrombosis or family history of thrombosis prior to signing or currently, or history of thrombophilia;
    8. Severe bleeding due to VWD within 2 years prior to screening, such as intracranial hemorrhage, esophageal variceal bleeding, etc.;
    9. Severe cardiac disease, such as unstable angina, congestive heart failure ( class >= III), severe arrhythmia ( > 500 ms, corrected by Fridericia formula), uncontrolled hypertension (systolic blood pressure >= 160 mmHg or diastolic blood pressure >= 100 mmHg), etc.;
    10. Female patients with menstrual abnormalities due to organic gynecological diseases (e.g., uterine fibroids, endometriosis, adenomyosis, etc.);
    11. Previous or current life-threatening malignant neoplasms or end-stage liver disease;
    12. Use of DDAVP or plasma-derived VWF-containing factor VIII concentrate, plasma-derived/recombinant VWF preparations, or antifibrinolytic therapy within 1 week prior to the first dose;
    13. Use of antithrombotic agents within 1 week prior to the first dose;
    14. Receipt of fresh blood/plasma or cryoprecipitate therapy within 2 weeks prior to the first dose;
    15. Receipt of vaccination within 1 month prior to the first dose or planned vaccination during the study period;
    16. Major surgery (major surgery defined as Grade III and IV surgeries) within 1 month prior to the first dose, or planned surgery during the study period;
    17. Enrollment in other clinical trials within 1 month prior to the first dose;
    18. History of drug abuse or alcohol dependence (alcohol dependence criteria: long-term drinking history exceeding 5 years, equivalent ethanol intake >= 40 g/day, or heavy drinking within 2 weeks, equivalent ethanol intake > 80 g/day. Ethanol amount (g) conversion formula = alcohol consumption (mL) x alcohol content (%) x 0.8);
    19. Presence of psychiatric disease or significant mental disorder, or other reasons resulting in incapacity or lack of cognitive ability;
    20. Plans for procreation or sperm donation throughout the study period up to 3 months after the last dose, or unwillingness to use effective physical measures (e.g., condoms);
    21. Presence of disease or other reasons rendering the patient unsuitable for clinical trial participation in the investigator's opinion (e.g., patient unlikely to benefit from the clinical trial);
    22. Patients whom the investigator considers to have poor compliance, rendering efficacy evaluation difficult or likelihood of completing the planned treatment course and follow-up low.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Multiple-dose exploratory efficacy trial consists of 4 cohorts

    Participants with Von Willebrand Disease will receive SR604 dose 1 as multiple SC injections every 4-weeks, or dose 2 as multiple SC injections every 4-weeks/6-weeks/8-weeks.

    Drug: SR604

Interventions

  • DrugSR604

    SR604 will be administered as SC injection.

06

What researchers measure

Primary outcomes

  1. Total annualized bleeding rate (ABR) after treatment

    Time frame: From baseline, through study completion, an average of 52 weeks

Secondary outcomes

  1. Annualized spontaneous bleeding rate

    Time frame: From baseline, through study completion, an average of 52 weeks

  2. Annualized traumatic bleeding rate

    Time frame: From baseline, through study completion, an average of 52 weeks

  3. Overall annualized bleeding rate, annualized spontaneous bleeding rate, and annualized traumatic bleeding rate

    Time frame: From baseline, through study completion, an average of 52 weeks

  4. EQ-5D-5L health questionnaire utility value

    Time frame: From baseline, through study completion, an average of 52 weeks

  5. Change in EQ-VAS score from baseline

    Time frame: From baseline, through study completion, an average of 52 weeks

  6. PK parameters after first dose:Peak Plasma Concentration (Cmax)

    Time frame: Day1

  7. Pharmacokinetic parameters after multiple doses: Peak Plasma Concentration (Cmax)

    Time frame: From baseline, through study completion, an average of 52 weeks

  8. Incidence of Adverse Events (AEs)

    Number of participants experiencing at least one AE

    Time frame: From baseline, through study completion, an average of 52 weeks

  9. PK parameters after first dose:Time to Peak Plasma Concentration (Tmax)

    Time frame: Day1

  10. Safety: Number and incidence of patients with anti-drug antibodies (ADA)

    Time frame: From baseline, through study completion, an average of 52 weeks

  11. Pharmacokinetic parameters after multiple doses: Time to Peak Plasma Concentration (Tmax)

    Time frame: From baseline, through study completion, an average of 52 weeks

  12. Incidence of Serious Adverse Events (SAEs)

    Number of participants experiencing at least one SAE

    Time frame: From baseline, through study completion, an average of 52 weeks

  13. Incidence of Adverse Events of Special Interest (AESIs)

    Number of participants experiencing at least one AESI

    Time frame: From baseline, through study completion, an average of 52 weeks

  14. Pharmacodynamic indicators:protein C

    Time frame: From baseline, through study completion, an average of 52 weeks

  15. Pharmacodynamic indicators:prothrombin time (PT)

    Time frame: From baseline, through study completion, an average of 52 weeks

  16. Pharmacokinetic parameters after multiple doses:Time to Peak Plasma Concentration (Tmax)

    Time frame: From baseline, through study completion, an average of 52 weeks

  17. Pharmacokinetic parameters after multiple doses: Area Under the Concentration-Time Curve from Zero to Last Quantifiable Time Point (AUC0-t)

    Time frame: From baseline, through study completion, an average of 52 weeks

Other outcomes

  1. Pharmacodynamic indicators:Protac-APTT (Protac-induced protein C-activated APTT assay)

    Time frame: From baseline, through study completion, an average of 52 weeks

  2. Change from baseline in PBAC score at Week 24 of treatment and over the total treatment period (including treatment period and extended treatment period) (females with menstruation only);

    Time frame: From baseline, through study completion, an average of 52 weeks

  3. Annualized menorrhagia bleeding rate at Week 24 of treatment and over the total treatment period (including treatment period and extended treatment period) (females with menstruation only);

    Time frame: From baseline, through study completion, an average of 52 weeks

  4. Categorization of replacement therapeutic agents prior to investigational product administration, at Week 24 of treatment, and over the total treatment period (including treatment period and extended treatment period).

    Time frame: From baseline, through study completion, an average of 52 weeks

07

Study locations

9 of 9 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 11, 2026
StartActual
Nov 26, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07640893
Responsible party
Sponsor
First posted
Jun 11, 2026
Start date
Nov 26, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 11, 2026

Study contacts

Research and Development
Contact
hanyu@raas-corp.com
862122130888

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SR604

Start the discussion